Loading, Please Wait...

CST: 21/10/2019 14:47:51   

CHF Solutions to Sponsor CT Theatre Session, “Personalized Medicine: Improving Clinical Outcomes with Novel Fluid Management Strategies” Moderated by Renowned Cardiothoracic Surgeon Daniel Beckles, M.D., Ph.D., at the 2019 AATS Annual Meeting

181 Days ago

EDEN PRAIRIE, Minn., April 23, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring a CT Theatre Session at the American Association for Thoracic Surgery Annual Meeting on Monday, May 6, 2019, 1:00-1:30 pm at the Metro Toronto Convention Center.

The panel titled, “Personalized Medicine: Improving Clinical Outcomes with Novel Fluid Management Strategies,” will include discussion on the use of the Aquadex FlexFlow® System to help manage risks associated with fluid overload in adult cardiac surgery patients. The discussion will be moderated by Daniel Beckles, M.D., Ph.D. (United Health Services Hospitals-Binghamton) and panel members will include Margarita Camacho, M.D. (Newark Beth Israel), Mehdi Oloomi, M.D. (Mount Sinai Health System), and Mark Small, M.S., PA-C (Medstar Franklin Square). In addition, the company will be exhibiting at the meeting in Booth #611, Hall A-C, during the conference, which is held from May 4-7.

“The use of ultrafiltration in post-cardiovascular surgery provides medical providers with an important solution to treat fluid overload,” said John Erb, chairman and CEO of CHF Solutions. “We are pleased to have Dr. Beckles moderate such a distinguished panel of industry experts for this CT Theatre Session and provide practitioners on clinical methodologies to optimize treatment outcomes in the post cardiovascular surgery setting.”

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the company’s plans for the American Association for Thoracic Surgery Annual Meeting. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

Source: CHF Solutions, Inc.

Is your business listed correctly on America’s largest city directory network of 1,000 portals?